Compare · CGIX vs ILMN
CGIX vs ILMN
Side-by-side comparison of Cancer Genetics, Inc. (CGIX) and Illumina Inc. (ILMN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CGIX and ILMN operate in Medical Specialities (Health Care), so they compete in similar markets.
- ILMN carries a market cap of $32.20B.
- ILMN has hit the wire 13 times in the past 4 weeks while CGIX has been quiet.
- ILMN has more recent analyst coverage (25 ratings vs 0 for CGIX).
- Company
- Cancer Genetics, Inc.
- Illumina Inc.
- Price
- -
- -
- Market cap
- -
- $32.20B
- 1M return
- -
- -22.85%
- 1Y return
- -
- +71.99%
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NASDAQ
- NASDAQ
- IPO
- n/a
- 2000
- News (4w)
- 0
- 13
- Recent ratings
- 0
- 25
Illumina Inc.
Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. The company provides instruments and consumables used in genetic analysis; and genotyping and sequencing services, instrument service contracts, and development and licensing agreements. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as sells through life-science distributors in various markets within Europe, the Asia-Pacific region, Latin America, the Middle East, and Africa. It has a collaboration agreement with Geneseeq Technology Inc. to develop comprehensive in-vitro diagnostic (IVD) NGS testing kits for cancer. The company was incorporated in 1998 and is headquartered in San Diego, California.
Latest CGIX
- SEC Form 4: John R Fletcher was granted 8,676 units of Common Stock
- SEC Form 4 filed by Marcus Boehm
- SEC Form 4 filed by Joanna Horobin
- SEC Form 4 filed by Howard Mcleod
- SEC Form 4 filed by Yung-Ping Yeh
- SEC Form 4 filed by R. Paul Hansen
- SEC Form 4 filed by E. Geoffrey Harris
- SEC Form 4 filed by Ralf Brandt
- SEC Form 4 filed by D.C. Andrew Lafrence
- SEC Form 4 filed by A John Roberts
Latest ILMN
- SVP, Chief Technology Officer Barnard Steven covered exercise/tax liability with 360 shares, decreasing direct ownership by 0.88% to 40,567 units (SEC Form 4)
- VP, Chief Accounting Officer Ericksen Scott D covered exercise/tax liability with 150 shares, decreasing direct ownership by 1% to 14,296 units (SEC Form 4)
- SVP, Chief People Officer Leckman Patricia covered exercise/tax liability with 208 shares, decreasing direct ownership by 0.98% to 21,120 units (SEC Form 4)
- Chief of Global Operations Pegels Kevin Carl covered exercise/tax liability with 604 shares, decreasing direct ownership by 2% to 28,434 units (SEC Form 4)
- Illumina advances MRD research portfolio with ultrasensitive duplex sequencing technology
- Director Meister Keith A. sold $66,560,212 worth of shares (281,433 units at $236.50) (SEC Form 4)
- Illumina selected to help bring precision medicine into everyday healthcare in Singapore
- SEC Form 10-Q filed by Illumina Inc.
- SEC Form 8-K filed by Illumina Inc.
- Illumina Reports Financial Results for Third Quarter of Fiscal Year 2026